<!DOCTYPE html>
<html lang="en" dir="auto">

<head>
<head>
    <title>cardiovascular medicine</title>
    <meta charset="utf-8">
    <meta name="description"
        content="Website meta description for google search results go here" />
    <meta name="dc.relation" content="https://trxiv.yorks0n.com" />
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <meta name="theme-color" content="#1A94D2" />

    

    
    
    
    <link rel="stylesheet" href="/css/main.min.css" media="screen">

</head>


<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<meta name="robots" content="index, follow">
<title>cardiovascular medicine | TRxiv2</title>
<meta name="keywords" content="">
<meta name="description" content="Repurposing of Glatiramer Acetate to Treat Heart Diseases
Authors: Aviel, G.; Elkahal, J.; Umansky, K. B.; Bueno-Levy, H.; Miyara, S.; Lendengolts, D.; Zhang, L.; Petrover, Z.; Kain, D.; Shalit, T.; Aharoni, R.; Arnon, R.; Mishaly, D.; Katz, U.; Nachman, D.; Ammar, M.; Asleh, R.; Amir, O.; Tzahor, E.; Sarig, R.
Score: 5.7, Published: 2023-10-02 DOI: 10.1101/2023.09.30.23295943
Myocardial injury may ultimately lead to adverse ventricular remodeling and development of heart failure (HF), which is a major cause of morbidity and mortality worldwide.">
<meta name="author" content="">
<link rel="canonical" href="https://trxiv.yorks0n.com/posts/cardiovascular-medicine/">
<link crossorigin="anonymous" href="/assets/css/stylesheet.904bd1e751cdd2a584fa6bed3fa1166dfd8ec9949ebfd0c4d69c5add5e17c23d.css" integrity="sha256-kEvR51HN0qWE&#43;mvtP6EWbf2OyZSev9DE1pxa3V4Xwj0=" rel="preload stylesheet" as="style">
<script defer crossorigin="anonymous" src="/assets/js/highlight.f413e19d0714851f6474e7ee9632408e58ac146fbdbe62747134bea2fa3415e0.js" integrity="sha256-9BPhnQcUhR9kdOfuljJAjlisFG&#43;9vmJ0cTS&#43;ovo0FeA="
    onload="hljs.initHighlightingOnLoad();"></script>
<link rel="icon" href="https://trxiv.yorks0n.com/favicon.ico">
<link rel="icon" type="image/png" sizes="16x16" href="https://trxiv.yorks0n.com/favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://trxiv.yorks0n.com/favicon-32x32.png">
<link rel="apple-touch-icon" href="https://trxiv.yorks0n.com/apple-touch-icon.png">
<link rel="mask-icon" href="https://trxiv.yorks0n.com/safari-pinned-tab.svg">
<meta name="theme-color" content="#2e2e33">
<meta name="msapplication-TileColor" content="#2e2e33">
<noscript>
    <style>
        #theme-toggle,
        .top-link {
            display: none;
        }

    </style>
    <style>
        @media (prefers-color-scheme: dark) {
            :root {
                --theme: rgb(29, 30, 32);
                --entry: rgb(46, 46, 51);
                --primary: rgb(218, 218, 219);
                --secondary: rgb(155, 156, 157);
                --tertiary: rgb(65, 66, 68);
                --content: rgb(196, 196, 197);
                --hljs-bg: rgb(46, 46, 51);
                --code-bg: rgb(55, 56, 62);
                --border: rgb(51, 51, 51);
            }

            .list {
                background: var(--theme);
            }

            .list:not(.dark)::-webkit-scrollbar-track {
                background: 0 0;
            }

            .list:not(.dark)::-webkit-scrollbar-thumb {
                border-color: var(--theme);
            }
        }

    </style>
</noscript><meta property="og:title" content="cardiovascular medicine" />
<meta property="og:description" content="Repurposing of Glatiramer Acetate to Treat Heart Diseases
Authors: Aviel, G.; Elkahal, J.; Umansky, K. B.; Bueno-Levy, H.; Miyara, S.; Lendengolts, D.; Zhang, L.; Petrover, Z.; Kain, D.; Shalit, T.; Aharoni, R.; Arnon, R.; Mishaly, D.; Katz, U.; Nachman, D.; Ammar, M.; Asleh, R.; Amir, O.; Tzahor, E.; Sarig, R.
Score: 5.7, Published: 2023-10-02 DOI: 10.1101/2023.09.30.23295943
Myocardial injury may ultimately lead to adverse ventricular remodeling and development of heart failure (HF), which is a major cause of morbidity and mortality worldwide." />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://trxiv.yorks0n.com/posts/cardiovascular-medicine/" /><meta property="article:section" content="posts" />
<meta property="article:published_time" content="2023-10-08T10:37:16+00:00" />
<meta property="article:modified_time" content="2023-10-08T10:37:16+00:00" />

<meta name="twitter:card" content="summary"/>
<meta name="twitter:title" content="cardiovascular medicine"/>
<meta name="twitter:description" content="Repurposing of Glatiramer Acetate to Treat Heart Diseases
Authors: Aviel, G.; Elkahal, J.; Umansky, K. B.; Bueno-Levy, H.; Miyara, S.; Lendengolts, D.; Zhang, L.; Petrover, Z.; Kain, D.; Shalit, T.; Aharoni, R.; Arnon, R.; Mishaly, D.; Katz, U.; Nachman, D.; Ammar, M.; Asleh, R.; Amir, O.; Tzahor, E.; Sarig, R.
Score: 5.7, Published: 2023-10-02 DOI: 10.1101/2023.09.30.23295943
Myocardial injury may ultimately lead to adverse ventricular remodeling and development of heart failure (HF), which is a major cause of morbidity and mortality worldwide."/>


<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BreadcrumbList",
  "itemListElement": [, 
    {
      "@type": "ListItem",
      "position":  2 ,
      "name": "Posts",
      "item": "https://trxiv.yorks0n.com/posts/"
    }, 
    {
      "@type": "ListItem",
      "position":  3 ,
      "name": "cardiovascular medicine",
      "item": "https://trxiv.yorks0n.com/posts/cardiovascular-medicine/"
    }
  ]
}
</script>
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BlogPosting",
  "headline": "cardiovascular medicine",
  "name": "cardiovascular medicine",
  "description": "Repurposing of Glatiramer Acetate to Treat Heart Diseases\nAuthors: Aviel, G.; Elkahal, J.; Umansky, K. B.; Bueno-Levy, H.; Miyara, S.; Lendengolts, D.; Zhang, L.; Petrover, Z.; Kain, D.; Shalit, T.; Aharoni, R.; Arnon, R.; Mishaly, D.; Katz, U.; Nachman, D.; Ammar, M.; Asleh, R.; Amir, O.; Tzahor, E.; Sarig, R.\nScore: 5.7, Published: 2023-10-02 DOI: 10.1101/2023.09.30.23295943\nMyocardial injury may ultimately lead to adverse ventricular remodeling and development of heart failure (HF), which is a major cause of morbidity and mortality worldwide.",
  "keywords": [
    
  ],
  "articleBody": " Repurposing of Glatiramer Acetate to Treat Heart Diseases\nAuthors: Aviel, G.; Elkahal, J.; Umansky, K. B.; Bueno-Levy, H.; Miyara, S.; Lendengolts, D.; Zhang, L.; Petrover, Z.; Kain, D.; Shalit, T.; Aharoni, R.; Arnon, R.; Mishaly, D.; Katz, U.; Nachman, D.; Ammar, M.; Asleh, R.; Amir, O.; Tzahor, E.; Sarig, R.\nScore: 5.7, Published: 2023-10-02 DOI: 10.1101/2023.09.30.23295943\nMyocardial injury may ultimately lead to adverse ventricular remodeling and development of heart failure (HF), which is a major cause of morbidity and mortality worldwide. Given the slow pace and substantial costs of developing new therapeutics, drug repurposing is an attractive alternative. Studies of many organs, including the heart, highlight the importance of the immune system in modulating injury and repair outcomes. Glatiramer-acetate (GA) is an immunomodulatory drug prescribed for patients with multiple sclerosis. Here we report that short-term GA treatment improves cardiac function and reduces scar area in a mouse model of acute myocardial infarction, as well as in a rat model of ischemic HF. We provide both in vivo and in vitro mechanistic evidence indicating that in addition to its immunomodulatory functions, GA exerts beneficial pleiotropic effects, including cardiomyocyte protection and enhanced angiogenesis, mediated partially by extracellular vesicles carrying a pro-reparative cargo. Finally, as GA is a widely used drug with established efficacy and safety history, we conducted a small, prospective, randomized trial to determine its effect on patients admitted to the hospital with acute decompensated HF (ADHF). Strikingly, a short-term add-on administration of GA, resulted in marked reduction in the cytokine surge and NT-proBNP levels, both associated with acute HF exacerbations. Overall, these findings demonstrate the efficacy of GA in attenuating acute myocardial injury and modulating the inflammatory process in animal models and humans and highlight the potential of GA as a future therapy for a myriad of heart diseases. One Sentence SummaryGlatiramer acetate promotes reparative processes in rodent models of cardiac injury and reduces the inflammatory process in ADHF patients.\nMapping the aetiological foundations of the heart failure spectrum using human genetics\nAuthors: Henry, A.; Mo, X.; Finan, C.; Chaffin, M. D.; Speed, D.; Issa, H.; Denaxas, S.; Ware, J. S.; Zheng, S. L.; Malarstig, A.; Gratton, J.; Bond, I.; Roselli, C.; Miller, D.; Chopade, S.; Schmidt, A. F.; Aagaard, B.; Abner, E.; Adams, L.; Andersson, C.; Aragam, K. G.; Arnlov, J.; Asselin, G.; Axelsson Raja, A.; Backman, J. D.; Bartz, T. M.; Biddinger, K. J.; Biggs, M. L.; Bloom, H. L.; Boersma, E.; Brandimarto, J.; Brown, M. R.; Brunak, S.; Bruun, M. T.; Buckbinder, L.; Bundgaard, H.; Carey, D. J.; Chasman, D. I.; Chen, X.; Cook, J. P.; Czuba, T.; de Denus, S.; Dehghan, A.; Delgado, G. E.; Doney, A\nScore: 5.5, Published: 2023-10-03 DOI: 10.1101/2023.10.01.23296379\nSummary paragraphHeart failure (HF), a syndrome of symptomatic fluid overload due to cardiac dysfunction, is the most rapidly growing cardiovascular disorder. Despite recent advances, mortality and morbidity remain high and treatment innovation is challenged by limited understanding of aetiology in relation to disease subtypes. Here we harness the de-confounding properties of genetic variation to map causal biology underlying the HF phenotypic spectrum, to inform the development of more effective treatments. We report a genetic association analysis in 1.9 million ancestrally diverse individuals, including 153,174 cases of HF; 44,012 of non-ischaemic HF; 5,406 cases of non-ischaemic HF with reduced ejection fraction (HFrEF); and 3,841 cases of non-ischaemic HF with preserved ejection fraction (HFpEF). We identify 66 genetic susceptibility loci across HF subtypes, 37 of which have not previously been reported. We map the aetiologic contribution of risk factor traits and diseases as well as newly identified effector genes for HF, demonstrating differential risk factor effects on disease subtypes. Our findings highlight the importance of extra-cardiac tissues in HF, particularly the kidney and the vasculature in HFpEF. Pathways of cellular senescence and proteostasis are notably uncovered, including IGFBP7 as an effector gene for HFpEF. Using population approaches causally anchored in human genetics, we provide fundamental new insights into the aetiology of heart failure subtypes that may inform new approaches to prevention and treatment.\nSamsung Galaxy Watch5 Pro and Withings Body+ generate electrical interference on CRT-Ds\nAuthors: Hansen, N.; Ha, G. B.; Colvin, P. R. T.; Freedman, R.; Bayes-Genis, A.; Steinberg, B. A.; Sanchez Terrones, B.\nScore: 2.0, Published: 2023-10-07 DOI: 10.1101/2023.10.05.23296573\nSmart consumer devices with bioimpedance sensing technology apply an electrical current to the body for health and wellness. However, whether these smart devices interfere with cardiac implantable electronic devices (CIEDs) remains unknown. We report electrical interference with benchtop testing from the Galaxy Watch5 Pro and smart scale Body+ to cardiac resynchronization therapy device generators from different manufacturers. These results highlight the need of establishing standard testing procedures to assess the safety of smart devices with bioimpedance sensing in patients with CIEDs.\nHeterogeneity of the Effect of Telemedicine Hypertension Management Approach on Blood Pressure: A Systematic Review and Meta-analysis of US-based Clinical Trials\nAuthors: Acharya, S.; Neupane, G.; Seals, A.; KC, M.; Giustini, D.; Sharma, S.; Taylor, Y. J.; Palakshappa, D.; Williamson, J. D.; Moore, J. B.; Bosworth, H.; Pokharel, Y.\nScore: 1.2, Published: 2023-09-15 DOI: 10.1101/2023.09.14.23295587\nBackgroundTelemedicine management of hypertension (TM-HTN) uses home blood pressure (BP) to guide pharmacotherapy and telemedicine-based self-management support (SMS). Optimal approach to implementing TM-HTN in the US is unknown. MethodsWe conducted a systematic review and a meta-analysis to examine the effect of TM-HTN vs. usual clinic-based care on BP and assessed heterogeneity by patient- and clinician-related factors. We searched US-based randomized clinical trials among adults from Medline, Embase, CENTRAL, CINAHL, PsycInfo, and Compendex, Web of Science Core Collection, Scopus, and two trial registries to 7/7/2023. Two authors extracted, and a third author confirmed data. We used trial-level differences in systolic BP (SBP), diastolic BP (DBP) and BP control rate at [\u0026ge;]6 months using random-effects models. We examined heterogeneity of effect in univariable meta-regression and in pre-specified subgroups [clinicians leading pharmacotherapy (physician vs. non-physician), SMS (pharmacist vs. nurse), White vs. non-White patient predominant trials (\u003e50% patients/trial), diabetes predominant trials ([\u0026ge;]25% patients/trial) and in trials that have majority of both non-White patients and patients with diabetes vs. White patient predominant but not diabetes predominant trials. ResultsThirteen, 11 and 7 trials were eligible for SBP, DBP and BP control, respectively. Differences in SBP, DBP and BP control rate were -7.3 mmHg (95% CI: - 9.4, -5.2), -2.7 mmHg (-4.0, -1.5) and 10.1% (0.4%, 19.9%), respectively, favoring TM-HTN. More BP reduction occurred in trials with non-physician vs. physician led pharmacotherapy (9.3/4.0 mmHg vs. 4.9/1.1 mmHg, P\u003c0.01 for both SBP/DBP), pharmacist vs. nurses provided SMS (9.3/4.1 mmHg vs. 5.6/1.0 mmHg, P=0.01 for SBP, P\u003c0.01 for DBP), and White vs. non-White patient predominant trials (9.3/4.0 mmHg vs. 4.4/1.1 mmHg, P\u003c0.01 for both SBP/DBP), with no difference by diabetes predominant trials. Lower BP reduction occurred in both diabetes and non-White patient predominant trials vs. White patient predominant but not diabetes predominant trials (4.5/0.9 mmHg vs. 9.5/4.2 mmHg, P\u003c0.01 for both SBP/DBP). ConclusionsTM-HTN is more effective than clinic-based care in the US, particularly when non-physician led pharmacotherapy and pharmacist provided SMS. Non-White patient predominant trials seemed to achieve lesser BP reduction. Equity conscious, locally informed adaptation of TM-HTN is needed before wider implementation. Clinical PerspectiveO_ST_ABSWhat Is New?C_ST_ABSO_LIIn this systematic review and meta-analysis of US-based clinical trials, we found that telemedicine management of hypertension (TM-HTN) was more effective in reducing and controlling blood pressure (BP) compared with clinic based hypertension (HTN) care. C_LIO_LIThe BP reduction was more evident when pharmacotherapy was led by non-physician compared with physicians and HTN self-management support was provided by clinical pharmacists compared with nurses, C_LIO_LINon-White patient predominant trials achieved lesser BP reductions than White patient predominant trials. C_LI What Are the Clinical Implications?O_LIBefore wider implementation of TM-HTN intervention in the US, locally informed adaptation, such as optimizing the team-based HTN care approach, can provide more effective BP control. C_LIO_LIWithout equity focused tailoring, TM-HTN intervention implemented as such can exacerbate inequities in BP control among non-White patients in the US. C_LI\n",
  "wordCount" : "1317",
  "inLanguage": "en",
  "datePublished": "2023-10-08T10:37:16Z",
  "dateModified": "2023-10-08T10:37:16Z",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://trxiv.yorks0n.com/posts/cardiovascular-medicine/"
  },
  "publisher": {
    "@type": "Organization",
    "name": "TRxiv2",
    "logo": {
      "@type": "ImageObject",
      "url": "https://trxiv.yorks0n.com/favicon.ico"
    }
  }
}
</script>
</head>

<body class="" id="top">
<script>
    if (localStorage.getItem("pref-theme") === "dark") {
        document.body.classList.add('dark');
    } else if (localStorage.getItem("pref-theme") === "light") {
        document.body.classList.remove('dark')
    } else if (window.matchMedia('(prefers-color-scheme: dark)').matches) {
        document.body.classList.add('dark');
    }

</script>

<header class="header">
    <nav class="nav">
        <div class="logo">
            <a href="https://trxiv.yorks0n.com" accesskey="h" title="TRxiv2 (Alt + H)">TRxiv2</a>
            <div class="logo-switches">
                <button id="theme-toggle" accesskey="t" title="(Alt + T)">
                    <svg id="moon" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <path d="M21 12.79A9 9 0 1 1 11.21 3 7 7 0 0 0 21 12.79z"></path>
                    </svg>
                    <svg id="sun" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <circle cx="12" cy="12" r="5"></circle>
                        <line x1="12" y1="1" x2="12" y2="3"></line>
                        <line x1="12" y1="21" x2="12" y2="23"></line>
                        <line x1="4.22" y1="4.22" x2="5.64" y2="5.64"></line>
                        <line x1="18.36" y1="18.36" x2="19.78" y2="19.78"></line>
                        <line x1="1" y1="12" x2="3" y2="12"></line>
                        <line x1="21" y1="12" x2="23" y2="12"></line>
                        <line x1="4.22" y1="19.78" x2="5.64" y2="18.36"></line>
                        <line x1="18.36" y1="5.64" x2="19.78" y2="4.22"></line>
                    </svg>
                </button>
            </div>
        </div>
        <ul id="menu">
        </ul>
    </nav>
</header>
<main class="main">
<article class="post-single">
  <header class="post-header">
    
    <h1 class="post-title">
      cardiovascular medicine
    </h1>
    <div class="post-meta"><span>updated on October 8, 2023</span>

</div>
  </header> 
  <div class="post-content"><div class="accordion accordion-flush" id="accordionFlushExample"><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.09.30.23295943">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.09.30.23295943" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.09.30.23295943">
        <p class="paperTitle">Repurposing of Glatiramer Acetate to Treat Heart Diseases</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.09.30.23295943" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.09.30.23295943" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Aviel, G.; Elkahal, J.; Umansky, K. B.; Bueno-Levy, H.; Miyara, S.; Lendengolts, D.; Zhang, L.; Petrover, Z.; Kain, D.; Shalit, T.; Aharoni, R.; Arnon, R.; Mishaly, D.; Katz, U.; Nachman, D.; Ammar, M.; Asleh, R.; Amir, O.; Tzahor, E.; Sarig, R.</p>
        <p class="info">Score: 5.7, Published: 2023-10-02 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.09.30.23295943' target='https://doi.org/10.1101/2023.09.30.23295943'> 10.1101/2023.09.30.23295943</a></p>
        <p class="abstract">Myocardial injury may ultimately lead to adverse ventricular remodeling and development of heart failure (HF), which is a major cause of morbidity and mortality worldwide. Given the slow pace and substantial costs of developing new therapeutics, drug repurposing is an attractive alternative. Studies of many organs, including the heart, highlight the importance of the immune system in modulating injury and repair outcomes. Glatiramer-acetate (GA) is an immunomodulatory drug prescribed for patients with multiple sclerosis. Here we report that short-term GA treatment improves cardiac function and reduces scar area in a mouse model of acute myocardial infarction, as well as in a rat model of ischemic HF. We provide both in vivo and in vitro mechanistic evidence indicating that in addition to its immunomodulatory functions, GA exerts beneficial pleiotropic effects, including cardiomyocyte protection and enhanced angiogenesis, mediated partially by extracellular vesicles carrying a pro-reparative cargo. Finally, as GA is a widely used drug with established efficacy and safety history, we conducted a small, prospective, randomized trial to determine its effect on patients admitted to the hospital with acute decompensated HF (ADHF). Strikingly, a short-term add-on administration of GA, resulted in marked reduction in the cytokine surge and NT-proBNP levels, both associated with acute HF exacerbations. Overall, these findings demonstrate the efficacy of GA in attenuating acute myocardial injury and modulating the inflammatory process in animal models and humans and highlight the potential of GA as a future therapy for a myriad of heart diseases.

One Sentence SummaryGlatiramer acetate promotes reparative processes in rodent models of cardiac injury and reduces the inflammatory process in ADHF patients.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.10.01.23296379">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.10.01.23296379" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.10.01.23296379">
        <p class="paperTitle">Mapping the aetiological foundations of the heart failure spectrum using human genetics</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.10.01.23296379" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.10.01.23296379" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Henry, A.; Mo, X.; Finan, C.; Chaffin, M. D.; Speed, D.; Issa, H.; Denaxas, S.; Ware, J. S.; Zheng, S. L.; Malarstig, A.; Gratton, J.; Bond, I.; Roselli, C.; Miller, D.; Chopade, S.; Schmidt, A. F.; Aagaard, B.; Abner, E.; Adams, L.; Andersson, C.; Aragam, K. G.; Arnlov, J.; Asselin, G.; Axelsson Raja, A.; Backman, J. D.; Bartz, T. M.; Biddinger, K. J.; Biggs, M. L.; Bloom, H. L.; Boersma, E.; Brandimarto, J.; Brown, M. R.; Brunak, S.; Bruun, M. T.; Buckbinder, L.; Bundgaard, H.; Carey, D. J.; Chasman, D. I.; Chen, X.; Cook, J. P.; Czuba, T.; de Denus, S.; Dehghan, A.; Delgado, G. E.; Doney, A</p>
        <p class="info">Score: 5.5, Published: 2023-10-03 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.10.01.23296379' target='https://doi.org/10.1101/2023.10.01.23296379'> 10.1101/2023.10.01.23296379</a></p>
        <p class="abstract">Summary paragraphHeart failure (HF), a syndrome of symptomatic fluid overload due to cardiac dysfunction, is the most rapidly growing cardiovascular disorder. Despite recent advances, mortality and morbidity remain high and treatment innovation is challenged by limited understanding of aetiology in relation to disease subtypes. Here we harness the de-confounding properties of genetic variation to map causal biology underlying the HF phenotypic spectrum, to inform the development of more effective treatments. We report a genetic association analysis in 1.9 million ancestrally diverse individuals, including 153,174 cases of HF; 44,012 of non-ischaemic HF; 5,406 cases of non-ischaemic HF with reduced ejection fraction (HFrEF); and 3,841 cases of non-ischaemic HF with preserved ejection fraction (HFpEF). We identify 66 genetic susceptibility loci across HF subtypes, 37 of which have not previously been reported. We map the aetiologic contribution of risk factor traits and diseases as well as newly identified effector genes for HF, demonstrating differential risk factor effects on disease subtypes. Our findings highlight the importance of extra-cardiac tissues in HF, particularly the kidney and the vasculature in HFpEF. Pathways of cellular senescence and proteostasis are notably uncovered, including IGFBP7 as an effector gene for HFpEF. Using population approaches causally anchored in human genetics, we provide fundamental new insights into the aetiology of heart failure subtypes that may inform new approaches to prevention and treatment.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.10.05.23296573">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.10.05.23296573" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.10.05.23296573">
        <p class="paperTitle">Samsung Galaxy Watch5 Pro and Withings Body&#43; generate electrical interference on CRT-Ds</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.10.05.23296573" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.10.05.23296573" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Hansen, N.; Ha, G. B.; Colvin, P. R. T.; Freedman, R.; Bayes-Genis, A.; Steinberg, B. A.; Sanchez Terrones, B.</p>
        <p class="info">Score: 2.0, Published: 2023-10-07 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.10.05.23296573' target='https://doi.org/10.1101/2023.10.05.23296573'> 10.1101/2023.10.05.23296573</a></p>
        <p class="abstract">Smart consumer devices with bioimpedance sensing technology apply an electrical current to the body for health and wellness. However, whether these smart devices interfere with cardiac implantable electronic devices (CIEDs) remains unknown. We report electrical interference with benchtop testing from the Galaxy Watch5 Pro and smart scale Body&#43; to cardiac resynchronization therapy device generators from different manufacturers. These results highlight the need of establishing standard testing procedures to assess the safety of smart devices with bioimpedance sensing in patients with CIEDs.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.09.14.23295587">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.09.14.23295587" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.09.14.23295587">
        <p class="paperTitle">Heterogeneity of the Effect of Telemedicine Hypertension Management Approach on Blood Pressure: A Systematic Review and Meta-analysis of US-based Clinical Trials</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.09.14.23295587" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.09.14.23295587" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Acharya, S.; Neupane, G.; Seals, A.; KC, M.; Giustini, D.; Sharma, S.; Taylor, Y. J.; Palakshappa, D.; Williamson, J. D.; Moore, J. B.; Bosworth, H.; Pokharel, Y.</p>
        <p class="info">Score: 1.2, Published: 2023-09-15 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.09.14.23295587' target='https://doi.org/10.1101/2023.09.14.23295587'> 10.1101/2023.09.14.23295587</a></p>
        <p class="abstract">BackgroundTelemedicine management of hypertension (TM-HTN) uses home blood pressure (BP) to guide pharmacotherapy and telemedicine-based self-management support (SMS). Optimal approach to implementing TM-HTN in the US is unknown.

MethodsWe conducted a systematic review and a meta-analysis to examine the effect of TM-HTN vs. usual clinic-based care on BP and assessed heterogeneity by patient- and clinician-related factors. We searched US-based randomized clinical trials among adults from Medline, Embase, CENTRAL, CINAHL, PsycInfo, and Compendex, Web of Science Core Collection, Scopus, and two trial registries to 7/7/2023. Two authors extracted, and a third author confirmed data. We used trial-level differences in systolic BP (SBP), diastolic BP (DBP) and BP control rate at [&amp;ge;]6 months using random-effects models. We examined heterogeneity of effect in univariable meta-regression and in pre-specified subgroups [clinicians leading pharmacotherapy (physician vs. non-physician), SMS (pharmacist vs. nurse), White vs. non-White patient predominant trials (&gt;50% patients/trial), diabetes predominant trials ([&amp;ge;]25% patients/trial) and in trials that have majority of both non-White patients and patients with diabetes vs. White patient predominant but not diabetes predominant trials.

ResultsThirteen, 11 and 7 trials were eligible for SBP, DBP and BP control, respectively. Differences in SBP, DBP and BP control rate were -7.3 mmHg (95% CI: - 9.4, -5.2), -2.7 mmHg (-4.0, -1.5) and 10.1% (0.4%, 19.9%), respectively, favoring TM-HTN. More BP reduction occurred in trials with non-physician vs. physician led pharmacotherapy (9.3/4.0 mmHg vs. 4.9/1.1 mmHg, P&lt;0.01 for both SBP/DBP), pharmacist vs. nurses provided SMS (9.3/4.1 mmHg vs. 5.6/1.0 mmHg, P=0.01 for SBP, P&lt;0.01 for DBP), and White vs. non-White patient predominant trials (9.3/4.0 mmHg vs. 4.4/1.1 mmHg, P&lt;0.01 for both SBP/DBP), with no difference by diabetes predominant trials. Lower BP reduction occurred in both diabetes and non-White patient predominant trials vs. White patient predominant but not diabetes predominant trials (4.5/0.9 mmHg vs. 9.5/4.2 mmHg, P&lt;0.01 for both SBP/DBP).

ConclusionsTM-HTN is more effective than clinic-based care in the US, particularly when non-physician led pharmacotherapy and pharmacist provided SMS. Non-White patient predominant trials seemed to achieve lesser BP reduction. Equity conscious, locally informed adaptation of TM-HTN is needed before wider implementation.

Clinical PerspectiveO_ST_ABSWhat Is New?C_ST_ABSO_LIIn this systematic review and meta-analysis of US-based clinical trials, we found that telemedicine management of hypertension (TM-HTN) was more effective in reducing and controlling blood pressure (BP) compared with clinic based hypertension (HTN) care.
C_LIO_LIThe BP reduction was more evident when pharmacotherapy was led by non-physician compared with physicians and HTN self-management support was provided by clinical pharmacists compared with nurses,
C_LIO_LINon-White patient predominant trials achieved lesser BP reductions than White patient predominant trials.
C_LI

What Are the Clinical Implications?O_LIBefore wider implementation of TM-HTN intervention in the US, locally informed adaptation, such as optimizing the team-based HTN care approach, can provide more effective BP control.
C_LIO_LIWithout equity focused tailoring, TM-HTN intervention implemented as such can exacerbate inequities in BP control among non-White patients in the US.
C_LI</p>
      </div>
    </div>
  </div>
</div>









<script src="/js/bundle.min.js" defer></script>



  </div>

  <footer class="post-footer">
    <ul class="post-tags">
    </ul>
  </footer>
</article>
    </main>
    
<footer class="footer">
    <span>&copy; 2023 <a href="https://trxiv.yorks0n.com">TRxiv2</a></span>
    <span>
        Â· Made by Yorkson
    </span>
</footer>
<a href="#top" aria-label="go to top" title="Go to Top (Alt + G)" class="top-link" id="top-link" accesskey="g">
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 12 6" fill="currentColor">
        <path d="M12 6H0l6-6z" />
    </svg>
</a>

<script>
    let menu = document.getElementById('menu')
    if (menu) {
        menu.scrollLeft = localStorage.getItem("menu-scroll-position");
        menu.onscroll = function () {
            localStorage.setItem("menu-scroll-position", menu.scrollLeft);
        }
    }

    document.querySelectorAll('a[href^="#"]').forEach(anchor => {
        anchor.addEventListener("click", function (e) {
            e.preventDefault();
            var id = this.getAttribute("href").substr(1);
            if (!window.matchMedia('(prefers-reduced-motion: reduce)').matches) {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView({
                    behavior: "smooth"
                });
            } else {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView();
            }
            if (id === "top") {
                history.replaceState(null, null, " ");
            } else {
                history.pushState(null, null, `#${id}`);
            }
        });
    });

</script>
<script>
    var mybutton = document.getElementById("top-link");
    window.onscroll = function () {
        if (document.body.scrollTop > 800 || document.documentElement.scrollTop > 800) {
            mybutton.style.visibility = "visible";
            mybutton.style.opacity = "1";
        } else {
            mybutton.style.visibility = "hidden";
            mybutton.style.opacity = "0";
        }
    };

</script>
<script>
    document.getElementById("theme-toggle").addEventListener("click", () => {
        if (document.body.className.includes("dark")) {
            document.body.classList.remove('dark');
            localStorage.setItem("pref-theme", 'light');
        } else {
            document.body.classList.add('dark');
            localStorage.setItem("pref-theme", 'dark');
        }
    })

</script>
</body>

</html>
